Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
MNK Mallinckrodt		$0.34	$0.75 ▼ $6.42	$1.58M	N/A	2.62 million shs	39,227 shs
NRBO NeuroBo Pharmaceuticals	$0.64	$0.67	$2.08 ▼ $4.41	$5.51M	-0.26	39,605 shs	44,036 shs
SPRB Spruce Biosciences	$8.75 -5.9%	$6.71	$0.06 ▼ $0.61	$4.92M	2.43	802,052 shs	863 shs
VAXX Vaxxinity	$0.04 +42,900.0%	$0.01	$0.00 ▼ $0.10	$5.45M	-24.16	6,962 shs	78,320 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
MNK Mallinckrodt	0.00%	0.00%	0.00%	0.00%	0.00%
NRBO NeuroBo Pharmaceuticals	0.00%	+0.58%	-4.12%	-6.50%	-84.04%
SPRB Spruce Biosciences	-5.93%	-23.18%	+15.86%	+79.76%	-73.00%
VAXX Vaxxinity	+42,900.00%	+72.00%	+42,900.00%	+186.67%	+115.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
MNK Mallinckrodt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
NRBO NeuroBo Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SPRB Spruce Biosciences	2.0532 of 5 stars	3.0	3.0	0.0	0.0	1.5	1.7	0.6
VAXX Vaxxinity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
MNK Mallinckrodt	0.00	N/A	N/A	N/A
NRBO NeuroBo Pharmaceuticals	0.00	N/A	N/A	N/A
SPRB Spruce Biosciences	2.00	Hold	$131.25	1,400.00% Upside
VAXX Vaxxinity	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
MNK Mallinckrodt	N/A	N/A	N/A	N/A	$47.48 per share	N/A
NRBO NeuroBo Pharmaceuticals	N/A	N/A	N/A	N/A	$1.50 per share	N/A
SPRB Spruce Biosciences	$4.91M	1.00	N/A	N/A	$1.88 per share	4.65
VAXX Vaxxinity	N/A	N/A	N/A	N/A	$0.11 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
MNK Mallinckrodt	N/A	-$116.19	N/A	N/A	N/A	-82.59%	20.32%	2.49%	N/A
NRBO NeuroBo Pharmaceuticals	-$12.47M	N/A	0.00	N/A	N/A	N/A	-189.12%	-122.31%	N/A
SPRB Spruce Biosciences	-$47.92M	-$99.25	N/A	N/A	N/A	-555.23%	-62.10%	-47.49%	N/A
VAXX Vaxxinity	-$56.93M	-$0.45	N/A	∞	N/A	N/A	N/A	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
MNK Mallinckrodt	N/A	N/A	N/A	N/A	N/A
NRBO NeuroBo Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SPRB Spruce Biosciences	N/A	N/A	N/A	N/A	N/A
VAXX Vaxxinity	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
MNK Mallinckrodt	1.18	0.57	0.31
NRBO NeuroBo Pharmaceuticals	N/A	2.41	2.41
SPRB Spruce Biosciences	0.01	5.36	5.36
VAXX Vaxxinity	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
MNK Mallinckrodt	83.74%
NRBO NeuroBo Pharmaceuticals	1.37%
SPRB Spruce Biosciences	91.71%
VAXX Vaxxinity	82.95%

Insider Ownership

Company	Insider Ownership
MNK Mallinckrodt	0.30%
NRBO NeuroBo Pharmaceuticals	1.05%
SPRB Spruce Biosciences	6.90%
VAXX Vaxxinity	64.06%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
MNK Mallinckrodt	2,700	13.17 million	13.13 million	Not Optionable
NRBO NeuroBo Pharmaceuticals	10	8.62 million	8.53 million	Not Optionable
SPRB Spruce Biosciences	20	562,000	37.54 million	Optionable
VAXX Vaxxinity	90	126.75 million	45.55 million	Not Optionable

MNK, NRBO, VAXX, and SPRB Headlines

Recent News About These Companies

Brain health

October 24, 2024 | newsweek.comN

Treatment Trials in Alzheimer's Disease

September 30, 2024 | msn.com

Is Vaxxinity Inc (VAXX) Stock a Good Investment?

September 19, 2024 | aaii.comA

Congress makes $4.5 trading stocks in a day; Here's the biggest winners

July 4, 2024 | finbold.comF

Vaxxinity UB-312 Parkinson's Trial Results Published in Nature Medicine

June 20, 2024 | globenewswire.com

Why Is Vaxxinity (VAXX) Stock Up 39% Today?

May 3, 2024 | investorplace.com

Why Is Vaxxinity (VAXX) Stock Down 58% Today?

April 22, 2024 | investorplace.com

Vaxxinity Plans to Delist Shares From Nasdaq

April 19, 2024 | marketwatch.com

Vaxxinity Issues Shareholder Letter

April 19, 2024 | globenewswire.com

Vaxxinity Announces Intention to Voluntarily Delist and Deregister its Class A Common Stock

April 19, 2024 | globenewswire.com

Vaxxinity to Present Clinical Data at the Annual Academy of Neurology 2024 Annual Meeting

March 28, 2024 | globenewswire.com

VAXX Stock Earnings: Vaxxinity Beats EPS for Q4 2023

March 27, 2024 | investorplace.com

Vaxxinity Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Updates

March 27, 2024 | globenewswire.com

Vaxxinity Announces Positive Target Engagement Data from Phase 1 Clinical Trial for Parkinson's Disease at AD/PD™ 2024

March 7, 2024 | globenewswire.com

Vaxxinity’s Heart Health Innovation to Reduce LDL Cholesterol Levels

February 15, 2024 | finance.yahoo.com

Vaxxinity’s Cholesterol Vaccine Candidate Successfully Lowers LDL-C: Preclinical Data Published

February 15, 2024 | finance.yahoo.com

Vaxxinity's Cholesterol Vaccine Candidate Successfully Lowers LDL-C: Preclinical Data Published

February 15, 2024 | globenewswire.com

Vaxxinity to Present Clinical and Preclinical Pipeline Data at AD/PD 2024

February 13, 2024 | finance.yahoo.com

Vaxxinity, UF Join Forces Against Neurodegenerative Diseases

January 30, 2024 | finance.yahoo.com

Vaxxinity Announces Research Collaboration on Active Immunotherapies for Neurodegenerative Diseases with University of Florida

January 30, 2024 | finance.yahoo.com

New MarketBeat Followers Over Time

MNK, NRBO, VAXX, and SPRB Company Descriptions

Mallinckrodt NYSE:MNK

Mallinckrodt Plc is a global specialty pharmaceuticals company. It develops, manufactures, markets and distributes both branded and generic specialty pharmaceutical products and medical imaging agents. It operates through the Specialty Brands and Specialty Generics segments. The Specialty Brands segment includes branded medicines. The Specialty Generics segment relates to specialty generic drugs, active pharmaceutical ingredients, as well as external manufacturing. The company was founded by Gustavo Mallinckrodt, Otto Mallinckrodt and Edward Mallinckrodt in 1867 and is headquartered in Blanchardstown, Dublin.

NeuroBo Pharmaceuticals NASDAQ:NRBO

$0.64 0.00 (0.00%)

As of 08/14/2025

NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), and has completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus (T2DM); and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in preclinical development for the treatment of obesity. The company's therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. It has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene. NeuroBo Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.

Spruce Biosciences NASDAQ:SPRB

$8.75 -0.55 (-5.93%)

As of 08/14/2025

Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. Spruce Biosciences, Inc. has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

Vaxxinity NASDAQ:VAXX

$0.04 +0.04 (+42,900.00%)

As of 08/15/2025 03:59 PM Eastern

Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology, cardiovascular diseases, and coronaviruses in the United States. Its product pipeline comprises UB-311, which is in phase 2 clinical trial that targets toxic forms of aggregated amyloid-b in the brain to fight alzheimer's disease; UB-312, which is in phase 1 clinical trial that targets toxic forms of aggregated a-synuclein in the brain to fight parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy; and VXX-301, which is in preclinical trial, an anti-tau product candidate for various neurodegenerative conditions, including alzheimer's disease, traumatic brain injury, and chronic traumatic encephalopathy. It also develops VXX-401, which is phase 1 clinical trial that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; UB-313 that targets calcitonin gene-related peptide to fight migraines; and UB-612, neutralizes the SARS-CoV-2 virus and is in phase 3 clinical trial. The company was incorporated in 2021 and is headquartered in Merritt Island, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time